This is an aggregated industry headline. Read the full story at FiercePharma →
It's unanimous: SCOTUS agrees with Hikma in 'skinny label' case vs. Amarin
With a resounding unanimous vote, the U.S. Supreme Court has sided with Hikma Pharmaceuticals, ruling that its generic version of Amarin's fish oil-derived cardiovascular drug Vascepa does not infringe patents held by the Irish company.
By FiercePharma
· Jun 5, 2026
· via FiercePharma
Image: FiercePharma
RxInsider combines reported facts with industry analysis and informed inference. Forward-looking reads, market commentary, and interpretive framing reflect analysis of available reporting and known facts, not confirmed outcomes.
Tags
theweekformat:headlineheadlineFiercePharma
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
The WeekFiercePharma ↗
From Indiana to Iceland, the FDA this week disclosed concerns raised during recent visits to a pair of manufac…
The WeekFierceBiotech ↗
After Eli Lilly dived into the psychedelics space with a $2.8 billion upfront acquisition of AtaiBeckley last …
The WeekBriefing
CMS and state actions under the American Rescue Plan Act and later legislation have made yearlong postpartum c…